A patient with Stage 4 Chronic Kidney Disease presents with bilateral pitting edema, crackles at the lung bases, and hyperkalemia. Which nursing intervention should be prioritized to address the patient's current condition?

C) Restrict fluid intake and administer furosemide as prescribed.

A) Encourage a high-protein diet to support nutritional status.

B) Administer a potassium-sparing diuretic to reduce fluid overload.

C) Restrict fluid intake and administer furosemide as prescribed.

D) Increase dietary potassium intake to counteract sodium imbalance.

A patient with Stage 4 Chronic Kidney Disease (CKD) presents with bilateral pitting edema, mild crackles at the lung bases, and hyperkalemia. Which nursing intervention should be prioritized to address the patient's current condition?

C) Administer loop diuretics as prescribed to decrease fluid overload.

A) Increase dietary potassium intake to improve electrolyte balance.

B) Encourage fluid intake to promote diuresis and reduce edema.

C) Administer loop diuretics as prescribed to decrease fluid overload.

D) Restrict sodium intake to manage hypertension and fluid retention.

A patient with advanced chronic kidney disease (CKD) is experiencing mild metabolic acidosis, persistent hypertension, and declining nutritional status. The healthcare team is considering adding an ACE inhibitor to manage blood pressure. Which nursing intervention is most appropriate prior to administering the ACE inhibitor?

B) Monitor the patient's current serum potassium level

A) Obtain a baseline blood pressure reading

B) Monitor the patient's current serum potassium level

C) Assess the patient's respiratory status

D) Review the patient's recent dietary intake

A patient with chronic kidney disease (CKD) and persistent hypertension is being considered for treatment with an ACE inhibitor. Given the patient's current lab results showing a potassium level of 5.5 mEq/L and a serum bicarbonate level of 18 mEq/L, what is the most appropriate initial nursing action?

B) Notify the healthcare provider about the hyperkalemia before administering the ACE inhibitor

A) Administer the ACE inhibitor as prescribed and monitor blood pressure hourly

B) Notify the healthcare provider about the hyperkalemia before administering the ACE inhibitor

C) Encourage increased dietary intake of potassium-rich foods to balance potassium levels

D) Administer a sodium bicarbonate supplement to address the mild metabolic acidosis

A patient with chronic kidney disease (CKD) stage 4 presents with anemia, hypertension, and declining renal function. The healthcare team is considering starting an ACE inhibitor and erythropoiesis-stimulating agents (ESAs). Which of the following nursing actions is most critical in this scenario to prevent complications?

D) Regularly monitor serum potassium levels and renal function after initiating the ACE inhibitor.

A) Educate the patient about the potential side effects of ESAs for anemia management.

B) Monitor the patient’s blood pressure and adjust antihypertensive medications as needed.

C) Assess the patient’s dietary intake to ensure adequate potassium levels.

D) Regularly monitor serum potassium levels and renal function after initiating the ACE inhibitor.

A patient with chronic kidney disease (CKD) presents with an eGFR of 25 mL/min/1.73m², hemoglobin level of 9.8 g/dL, and a blood pressure averaging 165/100 mmHg. The healthcare team is considering the introduction of erythropoiesis-stimulating agents (ESAs) and an ACE inhibitor. Which nursing intervention is most critical in this situation to ensure safe and effective care?

B) Monitor the patient's potassium levels and renal function frequently after starting the ACE inhibitor.

A) Educate the patient on the importance of adhering to a low-protein diet to slow CKD progression.

B) Monitor the patient's potassium levels and renal function frequently after starting the ACE inhibitor.

C) Administer iron supplements immediately to address potential iron deficiency before starting ESAs.

D) Initiate a referral to a dietitian to manage the patient's hypertension through dietary modifications.

A patient with chronic kidney disease is being treated with an erythropoiesis-stimulating agent and a low-dose ACE inhibitor. Recent lab results show a slight improvement in hemoglobin levels but reveal mild hyperkalemia with a serum potassium level of 5.5 mEq/L. The patient's blood pressure averages 155/95 mmHg. What is the most appropriate nursing intervention to address the hyperkalemia while considering the patient's current medication regimen?

C) Educate the patient on reducing dietary potassium intake to manage serum potassium levels.

A) Increase the dose of the ACE inhibitor to further improve blood pressure control.

B) Discontinue the erythropoiesis-stimulating agent to prevent further complications.

C) Educate the patient on reducing dietary potassium intake to manage serum potassium levels.

D) Administer a potassium-binding resin to immediately reduce serum potassium levels.

A patient with chronic kidney disease has been started on an erythropoiesis-stimulating agent (ESA) and a low-dose ACE inhibitor. Recent lab results show a serum potassium level of 5.5 mEq/L and blood pressure averaging 155/95 mmHg. What should the nurse prioritize in the care plan to manage these findings?

B) Educate the patient on reducing dietary potassium intake.

A) Increase the dose of the ACE inhibitor to better control blood pressure.

B) Educate the patient on reducing dietary potassium intake.

C) Encourage the patient to increase their fluid intake to dilute serum potassium.

D) Withhold the ESA medication until the potassium level normalizes.

A patient with chronic kidney disease has a serum potassium level of 5.0 mEq/L after diet modifications and medication adjustments. The patient's blood pressure remains elevated at 150/92 mmHg, and the healthcare team is considering adding a diuretic. Which additional assessment finding would most strongly support the decision to add a diuretic to the patient's treatment plan?

C) The patient has increased nocturia and fluid retention.

A) The patient's urinary output has significantly decreased.

B) The patient reports experiencing muscle cramps.

C) The patient has increased nocturia and fluid retention.

D) The patient's serum sodium level is slightly elevated.

A patient with chronic kidney disease (CKD) has shown improvement in serum potassium levels after dietary adjustments and changes in medication. However, the patient's blood pressure remains at 150/92 mmHg. Considering the need for further blood pressure management, which nursing intervention would be most appropriate to implement next?

B) Discuss with the healthcare provider the potential addition of a diuretic to the treatment regimen.

A) Increase dietary sodium intake to counteract potassium reduction.

B) Discuss with the healthcare provider the potential addition of a diuretic to the treatment regimen.

C) Encourage the patient to engage in more vigorous physical activity to reduce blood pressure.

D) Advise the patient to reduce fluid intake drastically to manage nocturia.

Chronic kidney disease - Nursing Case Study

Pathophysiology

• Primary mechanism: Chronic kidney disease (CKD) begins with nephron damage, often due to hypertension or diabetes, leading to glomerular hypertension and hyperfiltration. This causes progressive nephron loss and decreased glomerular filtration rate (GFR), impairing the kidneys' ability to filter waste and regulate fluid balance.

• Secondary mechanism: As nephron damage continues, compensatory mechanisms, such as increased angiotensin II production, further exacerbate glomerular hypertension and fibrosis. This results in structural damage and scarring (glomerulosclerosis), accelerating nephron loss and worsening kidney function.

• Key complication: Decreased GFR in CKD leads to accumulation of waste products and fluid imbalances, causing symptoms such as edema and electrolyte disturbances, and increasing the risk for cardiovascular complications.

Patient Profile

Demographics:

55-year-old male, retired factory worker

History:

• Key past medical history: Hypertension, Type 2 Diabetes, Hyperlipidemia

• Current medications: Lisinopril, Metformin, Atorvastatin, Furosemide

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increasing fatigue and swelling in the legs

• Key symptoms: Shortness of breath, decreased urine output, nausea

• Vital signs: Blood pressure 150/95 mmHg, Heart rate 88 bpm, Respiratory rate 20 breaths per minute, Temperature 98.6°F, Oxygen saturation 92% on room air

Section 1

Initial Assessment Findings:

Upon further assessment, the patient's physical examination reveals bilateral pitting edema in the lower extremities, extending to the mid-calves. Auscultation of the lungs indicates mild crackles at the bases, suggestive of fluid overload. The patient reports difficulty in climbing stairs due to shortness of breath, which has progressively worsened over the past two weeks. He also complains of persistent nausea, which has led to a decreased appetite and subsequent weight loss of approximately 5 pounds over the past month.

Lab results show a serum creatinine level of 2.8 mg/dL (increased from a baseline of 1.5 mg/dL six months ago), indicating a significant decline in renal function. Blood urea nitrogen (BUN) is elevated at 45 mg/dL. Electrolyte analysis reveals hyperkalemia with a potassium level of 5.8 mEq/L and mild hyponatremia with a sodium level of 132 mEq/L. The patient's eGFR is calculated at 25 mL/min/1.73 m², categorizing him in Stage 4 CKD. These findings suggest worsening renal impairment, likely exacerbated by poorly controlled hypertension and diabetes.

Given the current clinical picture, the priority is to address the fluid overload and potential electrolyte imbalances. Initiating a diuretic regimen adjustment, possibly with spironolactone, alongside dietary modifications to manage potassium levels, could be beneficial. Additionally, revisiting the patient's antihypertensive regimen to ensure optimal blood pressure control is crucial. The interdisciplinary team should consider a nephrology referral to manage the progression of CKD and discuss potential renal replacement therapies, if necessary. These steps will be critical to stabilize the patient's condition and prevent further complications, such as cardiovascular events or more severe electrolyte disturbances.

Section 2

As the care plan is implemented, the patient is closely monitored for changes in his status, particularly focusing on the response to the adjusted diuretic regimen. Over the next few days, the patient shows a mild improvement in respiratory symptoms, reporting slightly less shortness of breath. The bilateral pitting edema has slightly decreased, indicating some effectiveness of the diuretic therapy. However, new lab results reveal a concerning trend in the patient's electrolyte levels. The potassium level has decreased marginally to 5.5 mEq/L, but remains above the normal range, while the sodium level remains low at 130 mEq/L. Additionally, the patient's serum bicarbonate level is now 18 mEq/L, suggesting the development of a mild metabolic acidosis, a common complication in advanced CKD due to compromised acid excretion.

Despite these interventions, the patient's blood pressure remains suboptimal, averaging around 160/95 mmHg, indicating the need for further adjustments in the antihypertensive regimen. Given the persistent hypertension and the potential for further renal damage, the healthcare team considers adding an ACE inhibitor, which could help manage blood pressure while providing renal protection. However, the risk of exacerbating hyperkalemia necessitates careful monitoring and gradual titration.

The patient's declining nutritional status also demands attention. Despite dietary modifications aimed at reducing potassium intake, the patient's persistent nausea and poor appetite are concerning. A referral to a dietitian is made to develop a more tailored nutritional plan that addresses caloric needs while managing electrolyte balance, potentially incorporating supplements to counteract the weight loss and prevent further nutritional deficits. The interdisciplinary team continues to evaluate the patient's progress, emphasizing the importance of nephrology follow-up to explore future management strategies, including the possibility of renal replacement therapy as CKD progresses.

Section 3

As the healthcare team continues to monitor the patient closely, new diagnostic results highlight emerging concerns that necessitate further clinical reasoning and adjustments to the care plan. The latest lab work indicates a further decline in renal function, with the patient's estimated glomerular filtration rate (eGFR) dropping to 25 mL/min/1.73m², revealing progression of chronic kidney disease. Moreover, the patient's hemoglobin level has decreased to 9.8 g/dL, suggesting the development of anemia commonly associated with CKD. This anemia could be contributing to the patient's persistent fatigue and poor exercise tolerance, complicating his overall clinical picture and quality of life.

In light of these findings, the healthcare team considers the initiation of erythropoiesis-stimulating agents (ESAs) to address the anemia, while also assessing for potential iron deficiency, which might require supplementation. The patient's blood pressure remains a challenge, now averaging 165/100 mmHg, further stressing the importance of optimizing antihypertensive therapy. The decision to introduce an ACE inhibitor is carefully reconsidered, balancing the need for renal protection and blood pressure control against the risk of worsening hyperkalemia. The team plans to introduce the ACE inhibitor at a low dose, with frequent monitoring of potassium levels and renal function to mitigate potential adverse effects.

The patient's interdisciplinary care plan is further refined, with increased emphasis on dietary interventions and the potential need for more aggressive preparations for renal replacement therapy. The nephrology team is consulted to evaluate the patient's eligibility and readiness for dialysis or other renal replacement options. The patient and his family are engaged in ongoing discussions to ensure understanding and preparedness for future treatment decisions, reinforcing the importance of proactive management and comprehensive support as the patient's CKD progresses.

Section 4

As the healthcare team continues to fine-tune the patient's management plan, several days after the introduction of the erythropoiesis-stimulating agent (ESA) and the low-dose ACE inhibitor, new diagnostic results provide further insights into the patient's evolving clinical status. The latest laboratory findings indicate that while the hemoglobin level has shown a slight improvement, rising to 10.2 g/dL, suggesting a positive initial response to the ESA, the patient has developed mild hyperkalemia, with a serum potassium level of 5.5 mEq/L. This change prompts the team to reassess the current medication regimen and dietary potassium intake, ensuring that hyperkalemia does not progress to more severe levels.

Additionally, the patient's blood pressure has shown a slight improvement, now averaging 155/95 mmHg, indicating some benefit from the introduction of the ACE inhibitor. However, the persistent elevation in blood pressure, despite adjustments, suggests that a further review and possible titration of his antihypertensive regimen may be necessary. The patient's urinary output remains stable, though there is a noted increase in nocturia, which may be contributing to his fatigue. This symptom necessitates further evaluation to determine if it is related to fluid management or other underlying factors.

In response to these findings, the healthcare team emphasizes the importance of continued monitoring and frequent reassessment of both blood pressure and potassium levels. The dietary plan is adjusted to reduce potassium intake, and the patient is educated on the importance of adhering to dietary recommendations. The nephrology team continues to evaluate the patient's status and readiness for potential renal replacement therapy, while reinforcing the need for the patient and his family to remain actively engaged in care decisions. This comprehensive approach aims to manage the current complications effectively while preparing for possible future interventions as the patient's chronic kidney disease progresses.

Section 5

Several days after the adjustment to the patient's dietary plan to reduce potassium intake and the careful titration of the antihypertensive regimen, the healthcare team observes a notable change in the patient's status. The latest laboratory tests reveal that the patient's serum potassium level has decreased to 5.0 mEq/L, indicating a positive response to the dietary modifications and adjustments in medication. This improvement in potassium levels reduces the immediate risk of hyperkalemia-related complications, allowing the team to focus on optimizing other aspects of the patient's management.

However, the blood pressure remains a concern, with the patient's readings continuing to average around 150/92 mmHg. Despite a slight decrease, the persistent hypertension suggests that the current regimen may still require further modification. The healthcare team considers the addition of a diuretic to enhance blood pressure control, particularly given the patient's stable urinary output and increased nocturia, which could potentially be linked to fluid retention. Introducing a diuretic may help manage both the blood pressure and fluid status, alleviating some of the patient's fatigue and nocturia-related discomfort.

Simultaneously, the patient reports feeling slightly more energetic, which could be attributed to the gradual improvement in hemoglobin levels and better potassium control. This improvement in his overall well-being encourages more active participation in his care plan. The nephrology team continues to monitor renal function closely and discusses with the patient and his family the importance of regular follow-up visits and adherence to the treatment plan. As the team looks ahead, ongoing vigilance is required to anticipate and manage any new complications, ensuring that the patient maintains stability as his chronic kidney disease progresses.